increases toxicity of sufentanil by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.sufentanil SLisocarboxazid increases toxicity of sufentanil SL by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.sumatriptansumatriptan and isocarboxazid both increase serotonin levels. Avoid or Use Alternate Drug.isocarboxazid increases levels of sumatriptan by decreasing metabolism. Contraindicated.sumatriptan intranasalsumatriptan intranasal and isocarboxazid both increase serotonin levels. Avoid or Use Alternate Drug.isocarboxazid increases levels of sumatriptan intranasal by decreasing metabolism. Contraindicated.tapentadolisocarboxazid increases toxicity of tapentadol by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.tedizolidtedizolid, isocarboxazid. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Interaction with MAOIs were not studied in clinical trials; drugs within the same class(eg linezolid) are contraindicated with MAOIs.terbutalineisocarboxazid increases effects of terbutaline by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.tramadolisocarboxazid and tramadol both increase serotonin levels. Avoid or Use Alternate Drug.isocarboxazid increases toxicity of tramadol by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.umeclidinium bromide/vilanterol inhaledisocarboxazid and umeclidinium bromide/vilanterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiatedvalbenazineisocarboxazid, valbenazine. Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of valbenazine with MAOIs may increase monoamine neurotransmitter concentration in synapses, potentially increasing risk of serotonin syndrome or attenuating valbenazine effect.vilanterol/fluticasone furoate inhaledisocarboxazid and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiatedzolmitriptanzolmitriptan and isocarboxazid both increase serotonin levels. Avoid or Use Alternate Drug.isocarboxazid increases levels of zolmitriptan by decreasing metabolism. Contraindicated.Monitor Closely (51)benazeprilisocarboxazid, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.bretyliumisocarboxazid increases effects of bretylium by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Modify Therapy/Monitor Closely. Bretylium produces release of catecholamines from nerve endings. This increased catecholamine release is potentiated by MAOIs.buprenorphine subdermal implantisocarboxazid, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.buprenorphine, long-acting injectionisocarboxazid, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Modify Therapy/Monitor Closely. Concomitant use could result in life-threatening serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Buprenorphine long-acting injection is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.captoprilisocarboxazid, captopril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.chlorpropamideisocarboxazid increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.difenoxin hcldifenoxin hcl, isocarboxazid. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of serotonin syndrome.diphenoxylate hcldiphenoxylate hcl, isocarboxazid. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of serotonin syndrome.donepezil transdermaldonepezil transdermal, isocarboxazid. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.esketamine intranasalesketamine intranasal, isocarboxazid. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Closely monitor blood pressure with concomitant use of esketamine nasal with MAO-Is. .etomidateisocarboxazid increases levels of etomidate by pharmacodynamic synergism. Use Caution/Monitor.gabapentingabapentin, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.ganaxoloneisocarboxazid and ganaxolone both increase sedation. Use Caution/Monitor.glimepirideisocarboxazid increases effects of glimepiride by unknown mechanism. Use Caution/Monitor.glipizideisocarboxazid increases effects of glipizide by unknown mechanism. Use Caution/Monitor.glyburideisocarboxazid increases effects of glyburide by unknown mechanism. Use Caution/Monitor.green teagreen tea, isocarboxazid. Other (see comment). Use Caution/Monitor. Comment: Avoid combination or excessive consumption of green tea. Combination may increase risk of cardiac arrhythmias or severe hypertension can occur due to caffeine component of green tea.hydralazinehydralazine, isocarboxazid. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hypertension.indacaterol, inhaledindacaterol, inhaled, isocarboxazid. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with MAO inhibitors. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.insulin aspartisocarboxazid increases effects of insulin aspart by unknown mechanism. Use Caution/Monitor.insulin degludecisocarboxazid, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.insulin degludec/insulin aspartisocarboxazid, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.insulin detemirisocarboxazid increases effects of insulin detemir by unknown mechanism. Use Caution/Monitor.insulin glargineisocarboxazid increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.insulin glulisineisocarboxazid increases effects of insulin glulisine by unknown mechanism. Use Caution/Monitor.insulin inhaledisocarboxazid, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.insulin lisproisocarboxazid increases effects of insulin lispro by unknown mechanism. Use Caution/Monitor.insulin NPHisocarboxazid increases effects of insulin NPH by unknown mechanism. Use Caution/Monitor.insulin regular humanisocarboxazid increases effects of insulin regular human by unknown mechanism. Use Caution/Monitor.lasmiditanlasmiditan, isocarboxazid. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.isocarboxazid increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.lemborexantlemborexant, isocarboxazid. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.lithiumlithium, isocarboxazid. Mechanism: unknown. Use Caution/Monitor. Risk of malignant hyperpyrexia. Interactions esp. expected w/non selective MAOIs.lurasidonelurasidone increases effects of isocarboxazid by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.lurasidone, isocarboxazid. Either increases toxicity of the other by sedation. Use Caution/Monitor. Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maravirocmaraviroc, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.metforminisocarboxazid will increase the level or effect of metformin by unspecified interaction mechanism. Use Caution/Monitor.metrizamideisocarboxazid, metrizamide. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Risk of seizure. D/C MAO inhibitor 24h before admin. of metrizamide.oliceridineisocarboxazid, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.olodaterol inhaledisocarboxazid and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. MAO inhibitors prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasopium tinctureopium tincture, isocarboxazid. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of serotonin syndrome.oxymetazoline topicaloxymetazoline topical and isocarboxazid both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.phenylephrine ophthalmicisocarboxazid increases effects of phenylephrine ophthalmic by pharmacodynamic synergism. Use Caution/Monitor. Some systemic absorption of ophthalmic phenylephrine; reduce dose within 21 days of MAO inhibitors.pregabalinpregabalin, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.remifentanilremifentanil increases toxicity of isocarboxazid by serotonin levels. Modify Therapy/Monitor Closely. Increases risk of serotonin syndrome.remimazolamremimazolam, isocarboxazid. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.tapentadolisocarboxazid and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.tolazamideisocarboxazid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.tolbutamideisocarboxazid increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor.valerianvalerian and isocarboxazid both increase sedation. Use Caution/Monitor.yohimbeyohimbe increases effects of isocarboxazid by pharmacodynamic synergism. Use Caution/Monitor.Minor (15)amobarbitalisocarboxazid increases levels of amobarbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.butabarbitalisocarboxazid increases levels of butabarbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.butalbitalisocarboxazid increases levels of butalbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.celandinecelandine increases effects of isocarboxazid by pharmacodynamic synergism. Minor/Significance Unknown. Based on animal studies.cordycepscordyceps increases effects of isocarboxazid by pharmacodynamic synergism. Minor/Significance Unknown.disulfiramdisulfiram, isocarboxazid. Mechanism: unknown. Minor/Significance Unknown. Risk of delirium (case report).panax ginsengpanax ginseng increases effects of isocarboxazid by pharmacodynamic synergism. Minor/Significance Unknown.pentobarbitalisocarboxazid increases levels of pentobarbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.phenobarbitalisocarboxazid increases levels of phenobarbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.pleurisy rootpleurisy root decreases effects of isocarboxazid by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.primidoneisocarboxazid increases levels of primidone by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.secobarbitalisocarboxazid increases levels of secobarbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.sulfadiazineisocarboxazid increases levels of sulfadiazine by unspecified interaction mechanism. Minor/Significance Unknown.sulfamethoxazoleisocarboxazid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.sulfisoxazoleisocarboxazid increases levels of sulfisoxazole by unspecified interaction mechanism. Minor/Significance Unknown.5-HTPSerious - Use Alternative (1)isocarboxazid and 5-HTP both increase serotonin levels. Avoid or Use Alternate Drug.albuterolSerious - Use Alternative (1)isocarboxazid increases effects of albuterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.alfentanilSerious - Use Alternative (1)isocarboxazid increases toxicity of alfentanil by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.almotriptanSerious - Use Alternative (2)almotriptan and isocarboxazid both increase serotonin levels. Avoid or Use Alternate Drug. isocarboxazid increases levels of almotriptan by decreasing metabolism. Contraindicated.amitriptylineContraindicated (1)isocarboxazid and amitriptyline both increase serotonin levels. Contraindicated.amobarbitalSerious - Use Alternative (1)isocarboxazid, amobarbital. Other (see comment). Contraindicated. Comment: CNS depressants such as barbiturates should not be used in combination with isocarboxazid.Minor (1)isocarboxazid increases levels of amobarbital by decreasing metabolism. Minor/Significance Unknown. Theoretical interaction.amoxapineContraindicated (1)isocarboxazid and amoxapine both increase serotonin levels. Contraindicated.apraclonidineContraindicated (2)apraclonidine, isocarboxazid. Mechanism: unknown. Contraindicated. Contraindicated in mfr. prescribing info. isocarboxazid, apraclonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.arformoterolSerious - Use Alternative (1)isocarboxazid increases effects of arformoterol by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.armodafinilContraindicated (1)isocarboxazid increases effects of armodafinil by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.atomoxetineContraindicated (1)isocarboxazid increases effects of atomoxetine by pharmacodynamic synergism. Contraindicated. The use of atomoxetine with monoamine oxidase inhibitors (MAOIs) is contraindicated. Risk of acute hypertensive episode.belladonna and opiumSerious - Use Alternative (1)isocarboxazid increases toxicity of belladonna and opium by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.benazeprilMonitor Closely (1)isocarboxazid, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension.benzhydrocodone/acetaminophenSerious - Use Alternative (1)isocarboxazid increases toxicity of benzhydrocodone/acetaminophen by serotonin levels. Avoid or Use Alternate Drug. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma). Opioids are not recommended for patients taking MAOIs or within 14 days of stopping MAOIs. If urgent opioid treatment needed, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.benzphetamineContraindicated (1)isocarboxazid increases effects of benzphetamine by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.bretyliumMonitor Closely (1)isocarboxazid increases effects of bretylium by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Modify Therapy/Monitor Closely. Bretylium produces release of catecholamines from nerve endings. This increased catecholamine release is potentiated by MAOIs.brimonidineContraindicated (1)isocarboxazid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info.brompheniramineSerious - Use Alternative (1)isocarboxazid increases effects of brompheniramine by Other (see comment). Avoid or Use Alternate Drug.